Abstract
Background and Purpose In stroke, timely treatment is vital for preserving neurologic function. However, decision-making in neurocritical care is hindered by limited accessibility of neuroimaging and radiological interpretation. We evaluated an artificial intelligence (AI) system for use in conjunction with bedside portable point-of-care (POC)-MRI to automatically measure midline shift (MLS), a quantitative biomarker of stroke severity.
Materials and Methods POC-MRI (0.064 T) was acquired in a patient cohort (n=94) in the Neurosciences Intensive Care Unit (NICU) of an academic medical center in the follow-up window during treatment for ischemic stroke (IS) and hemorrhagic stroke (HS). A deep-learning architecture was applied to produce AI estimates of midline shift (MLS-AI). Neuroradiologist annotations for MLS were compared to MLS-AI using non-inferiority testing. Regression analysis was used to evaluate associations between MLS-AI and stroke severity (NIHSS) and functional disability (mRS) at imaging time and discharge, and the predictive value of MLS-AI versus clinical outcome was evaluated.
Results MLS-AI was non-inferior to neuroradiologist estimates of MLS (p<1e-5). MLS-AI measurements were associated with stroke severity (NIHSS) near the time of imaging in all patients (p<0.005) and within the IS subgroup (p=0.005). In multivariate analysis, larger MLS-AI at the time of imaging was associated with significantly worse outcome at the time of discharge in all patients and in the IS subgroup (p<0.05). POC-MRI with MLS-AI >1.5 mm was positively predictive of poor discharge outcome in all patients (PPV=70%) and specifically in patients with IS (PPV=77%).
Conclusion The integration of portable POC-MRI and AI provides automatic MLS measurements that were not inferior to time-consuming, manual measurements from expert neuroradiologists, potentially reducing neuroradiological burden for follow-up imaging in acute stroke.
Competing Interest Statement
The authors declare the following competing financial interests: Bradley Cahn, Mercy Mazurek, Matthew Yuen, Barbara Gordon-Kundu, and Gordon Sze (none); Prantik Kundu, Seyed Salehi, E. Brian Welch, Jo Schlemper, and Michal Sofka (employment by Hyperfine, Inc., Kundu at the time of research activities); Jonathan Rothberg (founder of Hyperfine, Inc.); and W. Taylor Kimberly and Kevin Sheth (research funding from Hyperfine, Inc.).
Funding Statement
This study was funded by an American Heart Association Collaborative Science Award 17CSA3355004. Additional research funding and the POC-MRI prototype was provided by Hyperfine, Inc. KNS is supported by the NIH (U24NS107136, U24NS107215, R01NR018335, R01NS110721, R03NS112859, U01NS106513, 1U01NS106513-01A1) and the American Heart Association (18TPA34170180). The authors would like to thank the volunteers for their participation and Dr. Lori Arlinghaus for assistance with manuscript preparation.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Our study was conducted under an institutional review board (IRB) protocol approved by the Yale Human Research Protection Program, and written informed consent was obtained from all participants or their legally authorized representatives prior to any research activities.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Declarations of interest: The authors declare the following competing financial interests: Bradley Cahn, Mercy Mazurek, Matthew Yuen, Barbara Gordon-Kundu, and Gordon Sze (none); Prantik Kundu, Seyed Salehi, E. Brian Welch, Jo Schlemper, and Michal Sofka (employment by Hyperfine, Inc., Kundu at the time of research activities); Jonathan Rothberg (founder of Hyperfine, Inc.); and W. Taylor Kimberly and Kevin Sheth (research funding from Hyperfine, Inc.).
Data Availability
All data produced in the present study are available upon reasonable request to the authors.
Abbreviations
- AI
- Artificial Intelligence
- CI
- Confidence Interval
- DL
- Deep Learning
- HS
- Hemorrhagic Stroke
- IPH
- Intraparenchymal Hemorrhage
- IS
- Ischemic Stroke
- MLS
- Midline Shift
- mRS
- Modified Rankin Scale
- NIHSS
- National Institutes of Health Stroke Scale
- POC-MRI
- Point-of-care MRI
- PPV
- Positive Predictive Value
- SAH
- Subarachnoid Hemorrhage
- TCD
- Transcranial Doppler
